VEGF-A levels in RP and non-RP eyes

Article

Sufferers of retinitis pigmentosa (RP) have a lower concentration of vascular endothelial growth factor A (VEGF-A) in the aqueous humour than non-sufferers, according to results of a study published in the August 2008 issue of Investigative Ophthalmology and Visual Science.

Sufferers of retinitis pigmentosa (RP) have a lower concentration of vascular endothelial growth factor A (VEGF-A) in the aqueous humour than non-sufferers, according to results of a study published in the August 2008 issue of Investigative Ophthalmology and Visual Science.

David Salom of the Department of Ophthalmology, University General Hospital of Valencia, Valencia, Spain and colleagues conducted a prospective, comparative control study, assessing the levels of VEGF-A in the aqueous humour of RP patients (n=16) through an enzyme-linked immunosorbent assay and comparing them to the levels of VEGF-A in the aqueous humour of otherwise healthy subjects preparing to undergo cataract surgery (n=16).

RP eyes had a mean VEGF-A level of 94.9±99.8 pg/mL; the control group had a mean VEGF-A level of 336.5±116.8 pg/mL.

The researchers observed that the VEGF-A level in non-RP eyes was significantly higher than in RP eyes, and concluded that the lower levels of VEGF-A could be a causative factor in the pathogenesis of RP.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.